Oralis SB Granted Oral Health Claim in Canada

636002872354088521021.jpg

31 May 2016 --- Canadian company Lallemand Health Solutions (LHS) has announced that their probiotic formula Oralis SB has been recognized for its benefits in dental health management by the Canadian Health Authorities, based on four randomized trials.

The following health claim has been approved by Health Canada: “Helps promote dental health through the control of Streptococcus mutans growth and plaque formation when used twice daily.”
 
In addition, the solution bears generic probiotic claims: Helps support intestinal/gastrointestinal health. Could promote a favorable gut flora. Source of probiotics.
 
The randomized trials submitted to the Canadian authorities and gathering a total of 330 children and 52 adults showed the following conclusions:
• Jindal et al. (2011): Oralis SB significantly reduces salivary S. mutans count as compared to a placebo in children. The authors concluded that Oralis SB “might be used as a suitable, easy and safe method for anti-caries prevention.”
• Jothika et al. (2015): Oralis SB used as mouthwash significantly reduces the count of cariogenic bacteria S. mutans found in the plaque in adults as compared to placebo and with similar efficacy than traditional antiseptic solutions (chlorhexidine and sodium fluoride mouthwashes).
• Thakkar et al., (2013): Oralis SB significantly reduces dental plaque formation in children, when compared to placebo, but also to chlorhexidine antiseptic mouthwash. It was concluded that Oralis SB “can be viewed as potential alternative to chlorhexidine mouthrinse for prevention of periodontal disease”.
• Purunaik et al. (2014): Oralis SB significantly reduces dental plaque formation in children as compared to placebo and chlorhexidine, and is even significantly more effective than chlorhexidine on gingivitis.
 
Altogether, these results indicate that this specific combination of Lactobacillus rhamnosus Rosell-11, Lactobacillus helveticus Rosell-52, Bifidobacterium longum Rosell-175 and Saccharomyces boulardii yeast represent a natural and effective approach to dental health prevention.
 
LHS has bases in more than 60 countries across 5 continents. Oralis SB is part of LHS’s portfolio of probiotics for Oral Health. Lallemand Inc. specializes in the development, production and marketing of yeast and bacteria, as well as other ingredients linked to these microorganisms or their markets.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Claiming concentration? Red Bull cautioned by UK advertising watchdog for “misleading” health claim

17 Jan 2019 --- UK advertising watchdog, the Advertising Standards Authority (ASA), has banned a poster for the energy drink Red Bull for reportedly implying that Red Bull has a beneficial impact on health, in particular, focus and concentration. Suggesting a product aids focus and concentration is a health claim, and therefore must comply with the claims authorized on the EU register. This is According to Regulation (EC) 1924/2006 on nutrition and health claims made on foods. Health claims are defined as those that state, suggest or imply a relationship between a food, or ingredient and health.

Health & Nutrition News

A fresh look at fiber: Nutrient holds “surprisingly” significant disease prevention role

14 Jan 2019 --- Higher intake levels of dietary fiber and whole grains are being linked with a lower risk of non-communicable diseases, body weight and cholesterol levels, according to an extensive analysis published in The Lancet. The research highlights the importance of carbohydrate quality in our diets, which may be particularly salient as low carb diets continue to trend. “We understood fiber to be good for us, but we didn't realize just how good it is,” study author, Andrew Reynolds of the University of Otago, New Zealand, tells NutritionInsight.

Health & Nutrition News

Brexit healthcare uncertainty: UK associations warn of staff shortages, increased costs and nutrition shortfalls

09 Jan 2019 --- Brexit may present a shadow of uncertainty for initiatives launched within the UK health and nutrition sector, most notably the National Health Service (NHS) Long Term Plan, which was published on January 7. Next Tuesday (January 15) marks the date on which the controversial Brexit deal, negotiated between Prime Minister Theresa May and the European Union (EU), will be approved or rejected by UK MPs. Yet, acceptance of the deal appears highly unlikely given the opposition from within the UK Conservative Party as well as other Remainers. 

Health & Nutrition News

On an all time high? Cannabis, hemp and CBD green lights fuel NPD surge

08 Jan 2019 --- As a string of regulatory greenlights have begun to move the cannabis plant and cannabis-derived products into an increasingly mainstream track, cannabis-derived products may well be the trend to watch in 2019. The FDA has signaled a softened stance on cannabis-derived products with its most recent move which has legalized hemp and Cannabidiol (CBD) derived from hemp. Such developments are exciting for the innovation front of food and drink products that contain cannabis-derived compounds. The future, it could be said, may be green.

Health & Nutrition News

World’s first celiac vaccine gains FDA fast-track designation during Phase 2 trial

03 Jan 2019 --- The world's first vaccine for people who have celiac disease, Nexvax2 from ImmusanT, Inc, has secured fast-track designation from the US Food and Drug Administration (FDA). The global Phase 2 study assessing Nexvax2 is currently recruiting patients, after rolling out late in 2018. Completion of the trial is expected in the second half of 2019. 

More Articles
URL : http://www.nutritioninsight.com:80/news/oralis-sb-granted-oral-health-claim-in-canada.html